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A B S T R A C T
Objectives: To describe real-world management and clinical and economic outcomes of patients with B-cell
precursor acute lymphoblastic leukemia (ALL) in Belgium, Greece and Switzerland.
Methods: This descriptive, retrospective medical chart review collected patient-level data in 2018 from adults
with ≥1 minimal residual disease (MRD) test during front-line ALL treatment. Data were stratified by MRD
status.
Results: Eighty-two patients were included (median age 44 years, 23 % Philadelphia chromosome-positive;
MRD-positive: n = 17, MRD-negative: n = 50, MRD result unknown: n = 15). HyperCVAD (32 %) and HOVON
(26 %) were the most frequently used front-line treatment protocols; 22 % of patients received stem cell
transplantation. Overall, 76 % of ALL patients were hospitalized (mean 1.1 hospitalization/month). Complete
hematological response (CRh) occurred in 66/82 patients (80 %). Median relapse-free survival from CRh was
32.7 months (MRD-positive: 11.7 months; MRD-negative: 33.3 months). Median overall survival from diagnosis
was 28.9 months (MRD-positive: 15.3 months; MRD-negative: not reached). Most patients (88 %) were MRD
tested during induction; testing rates considerably decreased thereafter (39 % during consolidation).
Conclusions: B-cell precursor ALL represents a clinical burden and impacts healthcare resources; MRD-positive
patients have worse prognosis than MRD-negative patients. Efforts should be made to adhere to recommenda-
tions for MRD testing in clinical guidelines.
1. Introduction
Acute lymphoblastic leukemia (ALL) accounts for approximately
15–20 % of all adult acute leukemias [1]. The HAEMACARE Working
Group estimated the overall crude incidence of ALL in Europe to be
1.28 per 100,000 individuals annually [2], qualifying this as a rare
disease [3]. In that analysis the ALL definition comprised all cases of
lymphoblastic lymphoma/acute [precursor cell] lymphatic leukemia,
including B-cell, T-cell and not otherwise specified (NOS) subtypes ir-
respective of age. In contrast to most cancers, the incidence of ALL
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peaks in children aged 0–14 years, with a crude incidence rate of 3.59
per 100,000 individuals in this age group [2]. B-cell precursor ALL is
the most common type of ALL; the HAEMACARE Working Group esti-
mated this to have an overall crude incidence of 0.08 per 100,000 in-
dividuals per year across age groups [2]. The definition used in that
study included both B-cell precursor lymphoblastic lymphoma and B-
cell precursor lymphoblastic leukemia. Overall, B-cell precursor ALL
(1.28) had a higher crude incidence rate per 100,000 individuals than
mature B-cell ALL (0.22; included Burkitt lymphoma, NOS and Burkitt
cell leukemia) [2]. Intensive chemotherapy regimens alongside novel
immunotherapies form the mainstay of treatment for ALL [4–6].
Nonetheless, treatment approaches are continuing to be optimized [7]
and real-world data on how currently available regimens are used in
clinical practice are lacking.
Although approximately 90 % of adults with ALL achieve complete
remission, most of them relapse and die of their disease [8]. None-
theless, overall survival (OS) rates have improved for adults with ma-
ture B-cell ALL [7], with much of this improvement linked to the
adoption of pediatric-inspired regimens [4]. In contrast however, sur-
vival remains poor for adults with B-cell precursor ALL [9], especially
for those in whom minimal residual disease (MRD) is not eradicated
during front-line treatment. MRD is an established prognostic factor in
ALL, which is defined as the presence of leukemic cells at levels below
the detection threshold using conventional morphologic methods
[10,11]. MRD positivity is the most important risk factor for hemato-
logic relapse [6,12], with MRD-positive (MRD+) patients having worse
prognosis than MRD-negative (MRD-) patients [10,13]. MRD status also
impacts on disease management. For example, MRD positivity is a
marker for high-risk disease and so is used to inform treatment deci-
sion-making [4,14]. A key therapeutic goal in ALL is the achievement of
MRD- status [3] early in treatment. Flow cytometry and polymerase
chain reaction (PCR) can identify trace levels of malignant cell bio-
markers in bone marrow samples from patients achieving a hematolo-
gical complete response (CRh) and so are commonly used to evaluate
MRD status. Although European guidelines recommend MRD testing in
patients with ALL during their first CRh [3], it is unclear whether this
occurs in clinical practice. There is, therefore, a need to understand how
ALL is managed and whether MRD positivity impacts on patient man-
agement and outcomes in routine clinical practice.
The overall objective of this descriptive study was to assess the
burden associated with B-cell precursor ALL in terms of clinical out-
comes and healthcare resource utilization (HCRU) in routine clinical
practice, as well as to collect real-world data on MRD testing.
2. Methods
2.1. Study design and patients
To fill the existing data gap in current literature, this study was
conducted in Belgium, Greece and Switzerland. A sample of physicians
who were personally responsible for initiating anti-tumor treatment in
patients with B-cell precursor ALL were invited to participate. Overall,
approximately 70 %, 33 % and 85 % of the 367, 180 and 150 Swiss,
Greek and Belgian hematologists in the database were invited, respec-
tively. Those who consented to participate in real-world research con-
ducted a retrospective medical chart review of eligible patients, ex-
tracting relevant data from their charts at their practice or study site in
2018. In total, 22 physicians were included, 15 from Greece, 4 from
Belgium and 3 from Switzerland. Most of the 22 physicians included
were hematologists (82 %); 9% were oncologists and 9% were hema-
tologist-oncologists, and most were based in academic centers (68 %).
The physicians had treated a median of 10 (range: 3–50) ALL patients in
the past year and had a median of 13 (range: 5–34) years’ experience in
managing ALL.
Eligible patients were aged ≥18 years and newly diagnosed with B-
cell precursor ALL (pre-B-cell, common B-cell or pro B-cell subtypes)
between January 1, 2011 and December 31, 2017. Patients also needed
to have received ≥1 MRD test during front-line induction or con-
solidation treatment. Inclusion started with the most recently diagnosed
patients to capture the advances in the disease management patterns in
recent years. This study was approved by the Freiburger
Ethikkommission international, Freiburg, Germany in December 2017.
After approval, patient-level data were abstracted between June and
November 2018.
Patients were observed from diagnosis until death, last available
record, or end of observation period, whichever occurred first. Data on
disease management, MRD status and testing patterns were collected
over the course of front-line treatment.
2.2. Variables analyzed
Patient characteristics are reported at ALL diagnosis and MRD status
at first available test result; characteristics were assessed overall and
stratified by MRD status and country. Patients were classified as MRD-,
if they tested negative in any of the tests during front-line treatment,
MRD unknown (those in whom an MRD test was performed but the test
result was unknown) and MRD+. The incidence of selected co-
morbidities was also assessed (cardiovascular disease, renal disease,
chronic pulmonary disease, and diabetes).
Front-line treatment patterns (e.g. treatment protocols, stem cell
transplantation [SCT], maintenance treatment, duration, etc) were re-
ported overall and stratified by MRD status and country. Front-line
treatment was defined as first-line ALL treatment until either end of
treatment, death or relapse (whichever occurred first). Front-line
treatment could include pre-induction and induction with che-
motherapy only, or followed by allogeneic/autologous SCT and con-
solidation, and maintenance therapy. Treatment duration was defined
as the time from front-line therapy initiation until the end of main-
tenance therapy (for patients receiving maintenance therapy), front-
line therapy termination, start of SCT (for patients receiving SCT), re-
lapse or death. Information regarding the treatment protocols men-
tioned here is available at http://www.hovon.nl/general/welcome.
html and in relevant guidelines [3,11]. Treatment duration was de-
fined as the time from front-line therapy initiation until the end of
maintenance therapy (for patients receiving maintenance therapy),
front-line therapy termination, start of SCT (for patients receiving SCT),
relapse or death.
Measures of HCRU included all hospitalizations (irrespective of
reason) and length of stay (LOS). As hospitalizations could occur mul-
tiple times for each patient, mean LOS was calculated based on the sum
of all the LOS’s (total LOS) for all hospitalizations for each patient. LOS
data were analyzed overall and by country. HCRU was investigated
from first MRD test until SCT (for patients receiving SCT), start of
maintenance therapy (for patients with maintenance therapy but no
SCT) or front-line therapy termination (all other patients). These
timeframes were chosen to reflect the real-world ALL disease manage-
ment options in the front line. To permit assessment of the impact of
MRD on outcomes, the start of follow-up for the HCRU analyses was the
first MRD test. To account for different follow-up times, the number of
hospital admissions and the sum of days hospitalized were divided by
the HCRU follow-up duration for each patient. This resulted in a stan-
dardized number of hospitalizations and length of hospital stay per
patient and per month of HCRU follow-up.
Clinical outcomes included the proportion of patients achieving a
CRh during front-line treatment, relapse-free survival (RFS) and OS.
Data were analyzed overall and stratified by MRD status. Data on
clinical outcomes were collected over the entire follow-up period and
median durations of RFS and OS estimated by Kaplan-Meier metho-
dology.
MRD testing patterns were reported overall and stratified by
country. Details of the methods used for testing (i.e. flow cytometry or
PCR) were also included.
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All analyses were descriptive (no statistical tests were conducted to
test for differences). All analyses were performed in R version 3.5.1




Overall, 82 patients were included in the study (63 %, 28 % and 8%
were from Greece, Belgium and Switzerland, respectively) and the ac-
tual median follow-up was 15.2 (range: 2–87) months (Table 1). The
patients’ median age was 44 (range: 19–80) years, with Belgian patients
appearing older at diagnosis (median age: 57 [range: 20–80] years)
than Greek patients (median age: 37 [range: 19–75] years) (Table A1).
Overall, 81 % of patients had an Eastern Cooperative Oncology Group
(ECOG) status of 0 or 1; proportions were 70 % and 83 % in Belgium
and Greece, respectively. In total, 23 % of patients had positive Phila-
delphia chromosome status; with similar proportions seen in Greek and
Belgian patients (25 % and 26 %, respectively). Overall, 23 % of pa-
tients had at least one of the assessed comorbidities at diagnosis, with
more Belgian patients (43 %) appearing to have comorbidities than
those from Greece (17 %). There were too few patients from Switzer-
land (n = 7) to draw comparisons with this country.
Most patients in this study (61 %) achieved MRD- status during
front-line treatment. Patients that remained MRD+ during front-line
treatment had a median age of 43 (range: 20–75) years at diagnosis
(MRD-: median of 35.5 [range: 19–73] years) and 41 % of the MRD+
group had positive Philadelphia chromosome status (MRD-: 16 %). Of
the 35 patients aged< 40 years in our study, 29 were MRD- and 28
were from Greece; 23 patients were both Greek and MRD- (total
number of MRD- Greek patients n = 33).
3.2. Front-line treatment patterns
Overall, the most commonly used front-line treatments were
HyperCVAD (32 %) and HOVON (26 %) protocols; the rest of the pa-
tients (42 %) received other protocols, including GMALL, GRAALL and
ALLIC-BFM (Table 2). Nearly all of the Belgian patients (91 %) were
treated following HOVON protocols, whereas the most common pro-
tocols in Greece were HyperCVAD (50 %) and GMALL (21 %) (Table
A2). All the Swiss patients (n = 7) received front-line treatment fol-
lowing the GRAALL protocol. Overall, the median duration of front-line
treatment was 6.9 (range: 1.0–43.5) months. In total, 22 % of patients
received SCT (13 % allogeneic, 2% autologous, 6% unknown), with
fewer Greek than Belgian patients receiving SCT (17 % and 35 %, re-
spectively). Across the study, 41 % of patients received maintenance
therapy (5 patients received both SCT and maintenance therapy and so
are included in both percentages; 4/5 patients received maintenance
therapy prior to receiving SCT). More Greek than Belgian patients re-
ceived maintenance treatment (48 % and 17 %, respectively). In total,
29 % of patients did not receive SCT or maintenance therapy due to
disease progression (50 %), death (29 %) or adverse events (25 %).
Patients with MRD- status appeared to have a longer median
duration of treatment (8.8 and 3.2 months), to be more likely to receive
maintenance treatment (54 % and 29 %) and to be less likely to dis-
continue treatment prior to initiation of SCT or maintenance therapy
(14 % and 41 %) than those with MRD+ status (Table 2).
3.3. HCRU
The follow-up for HCRU (from first MRD test until SCT, start of
maintenance therapy or front-line therapy termination) was a median
of 5.0 (range: 0–20.8) months for the 73 patients who had an MRD
testing date (and no missing end date). Overall, 56/73 patients (77 %)
were hospitalized; these 56 patients were hospitalized a mean of 1.1
Table 1
Patient and disease characteristics at diagnosis by MRD status (at first test).
Variable N in analysis ALL (N = 82) N in MRD analysis MRD- ALL (n = 50) MRD+ ALL (n = 17)
Age, years – median (range) 82 44 (19–80) 67 35.5 (19–73) 43 (20–75)
AYA population (15–39 years), n (%) 35 (42.7) 34 29 (58.0) 5 (29.4)
Country, n (%) 82 67
Belgium 23 (28.0) 10 (20.0) 0 (0.0)
Greece 52 (63.4) 33 (66.0) 17 (100.0)
Switzerland 7 (8.5) 7 (14.0) 0 (0.0)
MRD status, n (%) 82 67
MRD- 50 (61.0) 50 (100) –
MRD+ 17 (20.7) – 17 (100)
No test resulta 15 (18.3) – –
ECOG status, n (%) 80 67
0 37 (46.3) 28 (56.0) 8 (47.1)
1 28 (35.0) 16 (32.0) 3 (17.6)
2 12 (15.0) 5 (10.0) 4 (23.5)
3 3 (3.8) 1 (2.0) 2 (11.8)
Philadelphia chromosome positive, n (%) 82 19 (23.2) 67 8 (16.0) 7 (41.2)
CNS involvement, n (%) 82 67
Yes 3 (3.7) 2 (4.0) 1 (5.9)
No 72 (87.8) 48 (96.0) 16 (94.1)
Not tested/result unknown 7 (8.5) 0 (0) 0 (0)
Comorbities,b n (%) 82 67
Moderate/severe cardiovascular disease 8 (9.8) 4 (8.0) 1 (5.9)
Renal disease 5 (6.1) 0 (0.0) 0 (0.0)
Chronic pulmonary disease 8 (9.8) 3 (6.0) 3 (17.6)
Diabetes with chronic complications/end-stage disease 4 (4.9) 2 (4.0) 0 (0.0)
None of the above 62 (75.6) 44 (88.0) 12 (70.6)
Unknown 1 (1.2) 0 (0.0) 0 (0.0)
Leukocyte count, 109/L – median (range) 68 22 (1–50) 65 20 (1–49) 30 (4–42)
Bone marrow blast cell count, % – median (range) 69 75 (20–100) 66 80 (20–100) 67 (25–100)
Length of follow-up – median (range), months 82 15.2 (2.4–87.0) 67 23.6 (2.4–87.0) 14.0 (12.6–34.9)
a MRD tests were performed in 15 patients, but no result was recorded.
b Comorbidity categories are not mutually exclusive.
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times per month (standard deviation [SD]: 1.4). The standardized mean
LOS was 12.8 days (SD: 8.8); median LOS was 10.1 (range: 0.7–30.4)
days. Greek patients appeared to have more hospitalizations/month
(standardized mean: 1.06 and 0.88, respectively) and longer LOS per
patient per month (standardized mean: 14.0 and 9.5 days, respectively)
than Belgian patients. In general, both the standardized mean number
of hospitalizations (range: 0.1–10.1) and the total LOS (range: 0.7–30.4
days) varied considerably.
3.4. Clinical outcomes
Overall, a CRh occurred in 66/82 patients (80 %) during front-line
treatment. For the total population, median RFS from CRh (n = 62) was
32.7 months (95 % confidence interval [CI]: 21.1–not reached [NR])
and 30 patients (48 %) had an RFS event (hematological relapse: n =
19; death: n = 11) (Fig. 1A). The RFS curve plateaued at 35 % from 34
months after CRh until the end of follow-up. Median RFS was longer in
patients who tested MRD- in any test during front-line treatment (n =
46) than in those who remained MRD+ (n= 13; 33.3 months [95 % CI:
24.3–NR] and 11.7 months [95 % CI: 2.8–NR], respectively) (Fig. 1B).
The RFS curves plateaued at 38 % after 34 months and 30 % after 15
months for MRD- and MRD+ patients, respectively.
For the total population, median OS from diagnosis was 28.9
months (95 % CI: 23.4–NR) and 35 patients (43 %) died during follow-
up (Fig. 2A). The OS curve plateaued at 39 % from 39 months after
diagnosis until the end of follow-up. Overall, 71 %, 60 % and 39 % of
patients were alive at 1, 2 and 5 years, respectively. Of those with
known MRD status (n = 67), 28 patients (42 %) died during follow-up;
17/50 (34 %) of MRD- and 11/17 (65 %) of MRD+ patients. Median OS
was NR (95 % CI: 28.9–NR) in MRD- patients and the associated OS
curve plateaued at 50.1 % from 39 months after diagnosis until the end
of follow-up (Fig. 2B). Median OS was 15.3 months (95 % CI: 11–NR) in
MRD+ patients. With respect to those with MRD- status, 83 %, 74 %
and 50 % were alive at 1, 2 and 5 years, respectively. Survival rates at 1
and 2 years for the MRD+ group were 59 % and 33 %, respectively.
3.5. MRD testing patterns
Most patients (88 %) had their MRD status tested during induction;
testing rates considerably decreased thereafter, with only 39 % of
patients being MRD tested during consolidation (Table 3). Similar re-
sults were seen by country; 70 % and 96 % of Belgian and Greek pa-
tients were tested during induction and 39 % and 37 % were tested
during consolidation treatment (Table A2). For the 13 patients re-
ceiving SCT who had information available, 85 % were MRD tested
after SCT. For those receiving maintenance treatment who had in-
formation available (n = 29), 79 % were MRD tested during this stage
of treatment.
Overall, patients received a mean of 2.3 (SD: 1.7) MRD tests during
front-line therapy prior to SCT/maintenance treatment (Table 3); si-
milar results were seen in Belgium (2.0 [SD: 1.6]) and Greece (2.3 [SD:
1.9]) (Table A2). In patients with ≥1 MRD test (and a date of test
available; n = 73), their first test occurred a median of 1.2 months after
initiation of front-line treatment. In those patients with ≥2 test results
(and a date of test available; n = 41), the second test occurred a median
of 1.2 months later. In Belgium, the first MRD test occurred earlier
(median 1.2 and 1.4 months after front-line treatment initiation) and
the second MRD test followed later (median 1.6 and 1.1 months after
the first test) than in Greece. Overall, the frequency of MRD testing
varied over time with a peak at approximately 5 weeks after initiation
of front-line treatment (Fig. 3) (at weeks 5 and 9 in Greece; Figure
A1B). MRD testing continued over the course of the treatment (the last
test was conducted at 92 weeks post initiation), although the number of
tests reduced over time. In general, fewer tests were conducted per
week after week 10 (< 7 MRD tests performed per week after this
point). In Belgium, the number of MRD tests performed was too low to
draw any conclusions regarding any change in frequency of testing over
time (Fig. A1A).
Overall, flow cytometry was used for MRD testing in 60 % of tests
and PCR was used in 26 % (Table 3). PCR was the most common MRD
testing method in Belgium (67 %), whereas flow cytometry-based as-
says were most commonly used in Greece (72 %). Across the study, the
limit of sensitivity for determining MRD negativity was one leukemic
blast in 104 cells (1 × 104) in 71 % of tests.
4. Discussion
This medical chart review provides real-world data on treatment,
MRD testing patterns and clinical/economic outcomes for adult patients
(≥18 years old) receiving front-line treatment for B-cell precursor ALL
Table 2
Front-line treatment patterns.
Variable N in analysis, all/MRD ALL (N = 82) MRD- ALL (n = 50) MRD + ALL (n = 17)
Main treatment protocol used,a n (%) 82/67
HyperCVAD 26 (31.7) 18 (36.0) 7 (41.2)
HOVON 21 (25.6) 10 (20.0) 0 (0.0)
GMALL 11 (13.4) 5 (10.0) 5 (29.4)
GRAALL 9 (11.0) 9 (18.0) 0 (0.0)
ALLIC-BFM 5 (6.1) 4 (8.0) 1 (5.9)
Other protocol 10 (12.2) 4 (8.0) 4 (23.5)
Duration of treatment,b months – median (range) 79/65 6.9 (1,0–43.5) 8.8 (1.4–43.5) 3.3 (1.9–14.8)
Received SCT,c n (%) 82/67 18 (22.0) 12 (24.0) 4 (23.5)
Received maintenance therapy,c n (%) 82/67 34 (41.5) 27 (54.0) 5 (29.4)
Time to SCT from front-line therapy initiation, months – median (range) 18/16 6.6 (3.2–10.1) 7.4 (3.2–10.1) 6.1 (4.0–6.1)
Discontinued treatment prior to SCT or maintenance, n (%) 82/67 24 (29.3) 7 (14.0) 7 (41.2)
Reason for discontinuation, n (%) 24/14
Disease progression 12 (50.0) 2 (28.6) 5 (71.4)
Death 7 (29.2) 3 (42.9) 2 (28.6)
AE complications 6 (25.0) 2 (28.6) 1 (14.3)
Refusal 2 (8.3) 0 (0.0) 0 (0.0)
Other 12 (50.0) 2 (28.6) 5 (71.4)
a Used protocol versions included: ALLIC-BFM Version: 1/2/2000; GMALL Version: a/2003; GRAALL Version: 2003/2005/2014; HOVON Version: 71 + imatinib/
70/71/ALL-6A + imatinib/ALL-6B standard induction, consolidation and +/- SCT, and/or maintenance treatment/induction ALL; HyperCVAD Version: 1/2001/
2004/2010/2011/A/MD ANDERSON 2010/unknown.
b Includes maintenance and SCT (3 Greek patients had ongoing maintenance treatment at the end of the study and were excluded from the analysis).
c Five patients received SCT and maintenance therapy (4 patients received maintenance therapy before SCT, likely while they were awaiting SCT).
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in Belgium, Greece and Switzerland. Our results highlight that ALL is an
aggressive disease that is associated with poor prognosis and con-
siderable clinical and economic burden. Our findings also support
previous observations that MRD+ patients have worse prognosis than
MRD- patients [10] and highlight the clinical relevance of testing MRD
status outside of a clinical trial setting.
Although HCRU during front-line treatment varied considerably
between patients in our study, in general, a substantial amount of
HCRU was observed. Overall, 76 % of ALL patients were hospitalized,
with patients incurring 1 hospitalization/month on average and a mean
length of hospital stay of 13 days (median LOS was 10.1 days).
Additional hospitalizations may have occurred outside of the HCRU
hospitalization period, which spanned the time from first MRD test until
SCT, start of maintenance therapy or front-line therapy termination/
death. Likewise, as this study included those who had been recently
diagnosed with ALL, follow-up was short for some patients and any
hospitalization may have occurred after data abstraction. This may
mean that the amount of HCRU associated with ALL could have been
underestimated in this study.
Overall, median OS from diagnosis for the patients included in this
study was approximately 2.5 years. The similarity in shape of the OS
and RFS Kaplan-Meier curves, indicates a high correlation between OS
and RFS in ALL, with patients having a high risk of death after relapse.
This highlights the need for patients to receive effective front-line ALL
treatment that focuses on preventing relapse. A plateau in OS occurred
in approximately 39 % of patients from 39 months after diagnosis until
the end of follow-up, suggesting possible disease cure in these patients.
This plateau appeared to mainly be driven by MRD- patients, which
reinforces the importance of achieving MRD negativity as early as
possible during treatment. Although our real-world data support pre-
vious observations of the poor prognosis associated with MRD+ com-
pared with MRD- status, comparisons between these groups need to be
treated with caution due to the limited sample size. Furthermore, it
appeared that some prognostic variables at diagnosis (e.g. age,
Philadelphia chromosome status, etc) were correlated with MRD status
at first MRD test, with MRD+ patients generally showing more risk
Fig. 1. RFS from CRh (A) for all patients with ALL and (B) by MRD statusa.
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factors at diagnosis than MRD- patients. However, it should be noted
that the OS and RFS analyses are presented without censoring patients
at SCT because censoring excludes patients from the analyses and so
further reduces the limited sample size of some groups.
In this real-world study, MRD testing was most frequent during
induction and then generally declined over the course of treatment. The
highest number of MRD tests per week conducted was approximately 5
weeks after front-line therapy initiation, which is a timepoint often used
for treatment decision-making. This is especially true for newer proto-
cols such as GRAALL 2014 (EUDRA CT number: 2014-002146-44),
which uses MRD status to define disease risk and subsequent treatment.
The timing of the initial MRD test was similar to observations in a
previous study that reported a peak in MRD testing 4 weeks after the
start of induction therapy [15]. In general, fewer MRD test results were
reported 16 weeks after front-line treatment initiation in our study,
despite the fact that MRD results around this time are deemed clinically
more relevant for long-term prognosis than results from earlier time-
points [16–21]. This could be because patients died, were lost to follow-
up or relapsed and initiated second-line treatment. It could also be due
to the use of older treatment protocols in which MRD testing was not
mandatory at week 16. For instance, in Belgium nearly all patients were
treated using HOVON protocols including older regimens such as
HOVON-70. MRD testing is also a burdensome procedure, which may
mean physicians are reluctant to continue testing. The general lack of
testing beyond induction is a concern given the prognostic impact and
therapeutic consequences of MRD status [10,13]; it is important to
continue to evaluate MRD throughout treatment to ensure appropriate
patient management. In-line with this, current European Society of
Medical Oncology ALL guidelines state that molecular remission is the
most relevant independent prognostic factor for disease-free survival
and OS in patients with ALL [3]. Furthermore, they suggest that as MRD
is a well-established risk factor, quantification of this should be done
whenever possible for all patients.
Overall, and in Greece in particular, flow-cytometry-based methods
were most commonly used to test MRD status in our study. As flow
cytometry methods are not standardized, it can be difficult to compare
flow cytometry results between sites/countries.
Some between- and within-country differences in patient char-
acteristics and treatment patterns were observed in our study, sug-
gesting a lack of consensus on optimal ALL management. For example,
Fig. 2. OS (A) All patients with ALL and (B) by MRD statusa.
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compared with Greece, patients from Belgium appeared to have more
severe disease (i.e. they were older, had more comorbidities and a
higher bone marrow blast cell count) and had higher rates of SCT. This
may be a chance finding or because patients from Belgium were clus-
tered around centers of excellence in one area, which may treat patients
with more severe disease (who are more likely to receive SCT than
those with standard risks) [4]. Conversely, participating medical cen-
ters in Greece covered a wider geographical area and so may have seen
a more varied patient caseload. There is often a preference for the use of
certain ALL protocols within a given country and our results are sup-
portive of this. For instance, there was a much greater use of HOVON
protocols in Belgium than in Greece, probably due to the participation
of many of the Belgian physicians in the HOVON study group.
Overall, the findings of this study were similar to those reported
previously with respect to patient baseline characteristics, MRD testing
timepoints and outcomes [10,13,15,22]. Any observed differences may
Table 3
MRD testing patterns.
Variable N in analysis ALL
Patients being MRD tested during front-line therapy, n (%) 82a 81b (98.8)
Pre-inductionc 82a 11 (13.4)
Inductionc 82a 72 (87.8)
Consolidationc 82a 32 (39.0)
Otherc 82a 14 (17.1)
During hospitalization for SCTc 13 5 (38.5)
Post-SCTc,d 13 11 (84.6)
During maintenancec,e 29 23 (79.3)
Number of MRD tests per patient during front-line therapy prior to SCT or maintenance – mean (SD) median (range) 82a 2.3 (1.7) 2 (0–9)
Pre-induction – mean (SD) median (range) 82a 0.1 (0.3) 0 (0–1)
Induction – mean (SD) median (range) 82a 1.3 (0.9) 1 (0–5)
Consolidation – mean (SD) median (range) 82a 0.6 (0.9) 0 (0–4)
Other – mean (SD) median (range) 82a 0.3 (0.7) 0 (0–5)
Method used to test MRD status, n (%) 217
Flow cytometry 130 (59.9)
PCR 57 (26.3)
Time from start of front-line therapy to first MRD test, months – median (range) 73 1.2 (0–11.7)
Time from first to second MRD test, months – median (range) 41 1.2 (0–10.8)
a Includes patients who were MRD tested but for whom no MRD status result was available.
b One patient was recorded as being MRD tested during front-line therapy, but the number of MRD tests performed was documented as 0, therefore, they were
assumed to not have been MRD tested for the purpose of this analysis; Nearly 100 % of patients had an MRD test result during front-line therapy, as having at least 1
MRD test in front line was a requirement for inclusion in the study.
c Patients could be MRD tested during multiple stages of treatment.
d Includes those patients who received SCT (with or without maintenance) who had MRD data available post SCT.
e Includes only those patients who received maintenance and no SCT.
Fig. 3. MRD testing patterns during front-line ALL treatment.
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be due to differences in study design (e.g. one previous study was based
on the results of a physician survey that included estimated patient
management data [15], one included a variety of ALL patients [10] and
another only included responders [22]). In contrast to these other
publications, the current study purely reports retrospective data on how
patients were managed in routine clinical practice in Belgium, Greece
and Switzerland.
A strength of this study is that it provides real-world data on the
management and outcomes of adults with B-cell precursor ALL from
three European countries, which are rarely studied. The overall sample
size in this study (n = 82) was relatively large for this rare disease and
is larger than in many recent observational studies in adult ALL
[23–28]. However, it was small for some subgroups (e.g. MRD+ pa-
tients). The relatively high number of patients who were MRD tested
but had no available test result (18 %) further reduced sample size in
the MRD analyses. There are several possible explanations for these
missing results. For example, the results may have been stored within
the HOVON study group, who conducted the tests for the Belgian
physicians (13/15 missing results were from Belgium). In the HOVON
studies, MRD testing was part of the protocol, but since this was con-
sidered experimental at that point, the results were not communicated
to the investigators. In addition, it is common practice to test MRD
status in SCT-eligible patients. The patients without a test result were
older (median age: 64 [range 39–80] years), probably had a worse
prognosis (a low proportion [3/15: 20 %] achieved a CRh) and were
unlikely to be eligible for SCT (only 2/15 [13 %] received SCT), so their
test results may have been viewed as unimportant. The time burden on
physicians required to complete the electronic case report forms may
also have been a factor. Nonetheless, the fact that all 82 patients re-
ceived an MRD test but for 18 %, their results were not known suggests
a potential educational need for physicians regarding the importance
and prognostic impact of MRD status. Alternatively, this may be a
historical artefact and practice may have changed since the time these
patients were managed.
In summary, these real-world data are supportive of B-cell precursor
ALL being an aggressive disease associated with considerable clinical
burden, which also impacts on HCRU. The poorer prognosis associated
with MRD+ highlights the clinical relevance of MRD testing outside of
a clinical trial setting and supports achievement of MRD- status as a key
treatment goal for ALL patients undergoing front-line treatment. In this
study MRD testing was not performed in-line with current guidelines
(GRALL [29]; HOVON [30], HYPERCVAD [31]) and so there is room for
improvement with respect to this in clinical practice. Additional testing
of MRD status beyond the induction stage and regularly throughout a
patient’s treatment journey may help improve outcomes by permitting
appropriate patient management based on MRD status. Furthermore,
front-line treatment patterns varied overall and between countries in
this study suggesting a lack of consensus on optimal management of this
disease. As there is a high risk of death following relapse in ALL, it is
important that the most effective available therapies are used first in
this aggressive disease to limit the risk of relapse.
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